Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

Stay updated with real-time stock market news, Sensex & Nifty movements, top gainers and losers, expert analysis, IPO updates ...

In July 2025, global markets have been navigating a complex landscape marked by new U.S. tariff announcements and mixed economic signals, with the Nasdaq Composite Index showing resilience amidst ...

In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a ...

Simulations Plus Inc. reported lower than expected sales and reduced guidance due to cautious biopharma spending.

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

IPO stocks like Circle and CoreWeave have highlighted a revived U.S. IPO market. But can the rebound in valuations last?

U.S. Bancorp notched a rise in earnings for the latest quarter as it benefited from a lower loan-loss provision and growth in fee income. The healthcare-products maker trimmed and narrowed its ...